Sight Sciences (SGHT) Net Income towards Common Stockholders (2020 - 2026)
Sight Sciences (SGHT) posted Net Income towards Common Stockholders of -$4.4 million for Q2 2026, up 65.75% on a QoQ basis from -$13.0 million in Q1 2026, and up 62.77% year-over-year from -$2.7 million in Q2 2025.
Analysis
Sight Sciences (SGHT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Sight Sciences has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$4.4 million in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 62.77% year-over-year to -$4.4 million in Q2 2026; TTM through Jun 2026 was -$21.7 million, a 55.76% increase from a year earlier, with the FY2025 full-year figure at -$30.3 million, up 41.08% from the prior year.
- Net Income towards Common Stockholders was -$4.4 million for Q2 2026 at Sight Sciences, up from -$13.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $3.9 million in Q4 2025, with the low at -$23.8 million in Q2 2022.
- Average Net Income towards Common Stockholders over 5 years is -$13.4 million, with a median of -$13.0 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders sank 90.06% in 2022, then jumped 133.05% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$16.9 million in 2022, then jumped by 36.77% to -$10.7 million in 2023, then retreated by 10.8% to -$11.8 million in 2024, then soared by 133.05% to $3.9 million in 2025, then slumped by 213.56% to -$4.4 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.4 million (Q2 2026), -$13.0 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.42 Bn | 178.82 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.16 Bn | 118.94 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 118.41 Bn | 109.59 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.45 Bn | 100.98 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.47 Bn | 65.93 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.71 Bn | 45.46 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.95 Bn | 32.50 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.24 Bn | 30.29 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.17 Bn | 20.68 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Sight Sciences | 443.68 Mn | 363.92 Mn | 21.37 Mn | -4.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.45 Mn |
| Mar 31, 2026 | -12.98 Mn |
| Dec 31, 2025 | 3.92 Mn |
| Sep 30, 2025 | -8.17 Mn |
| Jun 30, 2025 | -11.94 Mn |
| Mar 31, 2025 | -14.15 Mn |
| Dec 31, 2024 | -11.85 Mn |
| Sep 30, 2024 | -11.07 Mn |
| Jun 30, 2024 | -12.33 Mn |
| Mar 31, 2024 | -16.27 Mn |
| Dec 31, 2023 | -10.69 Mn |
| Sep 30, 2023 | -13.04 Mn |
| Jun 30, 2023 | -14.75 Mn |
| Mar 31, 2023 | -17.07 Mn |
| Dec 31, 2022 | -16.91 Mn |
| Sep 30, 2022 | -22.23 Mn |
| Jun 30, 2022 | -23.84 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -15.94 Mn |
| Sep 30, 2021 | -17.17 Mn |